Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 XL184 versus placebo in advanced medullary thyroid cancer
NL-OMON35202Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Medullary Thyroid Cancer (MTC) comparing XL184 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2009; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON35202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35202.